Billiontoone Inc(BLLN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | - | P/E | 186.4 | EPS (ttm) | 0.62 | Insider Own | 49.2% | Shs Outstand | 42.3M | Perf Week | 8.67% |
| Market Cap | 5.42B | Forward P/E | 114.39 | EPS next Y | 29.41% | Insider Trans | -1.93% | Shs Float | 24.0M | Perf Month | 7.89% |
| Enterprise Value | 5.01B | PEG | 0.87 | EPS next Q | 0.15 | Inst Own | 28.74% | Short Float | 12.23% | Perf Quarter | -17.14% |
| Income | 0.03B | P/S | 13.64 | EPS this Y | 454.13% | Inst Trans | 4.57% | Short Ratio | 4.49 | Perf Half Y | 53.02% |
| Sales | 0.40B | P/B | 10.02 | EPS next 5Y | 131.37% | ROA | 6.13% | Short Interest | 2.93M | Perf YTD | 40.32% |
| Book/sh | 11.46 | P/C | 9.88 | EPS past 3/5Y | - | ROE | 9.05% | 52W High | -23.66% ($150.44) | Perf Year | - |
| Cash/sh | 11.63 | P/FCF | 163.37 | Sales past 3/5Y | 106.24% - | ROIC | 4.74% | 52W Low | 85.35% ($61.96) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 90.18 | EPS Y/Y TTM | 201.39% | Gross Margin | 71.27% | Volatility(W/M) | 5.1% 6.48% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 12.62 | Sales Y/Y TTM | 90.12% | Oper. Margin | 10.9% | ATR (14) | 5.94 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.31 | EPS Q/Q | 2789.09% | Profit Margin | 8.04% | RSI (14) | 61.96 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.69 | Sales Q/Q | 64.4% | SMA20 | 11.1% ($103.37) | Beta | - | Target Price | $129 |
| Payout | - | Debt/Eq | 0.27 | Earnings | 2026/11/4 | SMA50 | 11.01% ($103.45) | Rel Volume | 0.89 | Prev Close | $114 |
| Employees | 713 | LT Debt/Eq | 0.26 | EPS/Sales Surpr. | -18.17% 0.17% | SMA200 | 19.2% ($96.34) | Avg Volume(3M) | 0.65M | Price | $114.84 |
| IPO | 2025/11/6 | Option/Short | Yes/Yes | Trades | 9356 | Volume | 583,249 | Change | 0.74% |
A diagnostics company that leverages molecular diagnostic technology to offer prenatal testing and oncology diagnostics. Using its proprietary molecular counting technology, it provides non-invasive prenatal testing, single-gene disease screening, and liquid biopsy-based tumor diagnostics, and is growing rapidly with differentiated test accuracy. An emerging player in the prenatal and oncology diagnostics space.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded about as much as usual. That is 89% of its average volume.
Next earnings report: November 4
5 days to go.
BLLN makes money exceptionally well
Of every $100 in sales, $10.90 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +454.1% this year.
Tap to view numbers
However, it looks expensive
For a company expected to earn $100 next year, you would pay $11,439. Peers typically go for $2,860.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 28.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #20 of 44 in the industry
Based on market cap of $5B.
RDNT#19 Radnet Inc $6B PER - BLLN#20 Billiontoone Inc $5B PER 186.4 
SHC#21 Sotera Health Co $5B PER 32.9 
ADPT#22 Adaptive Biotechnologies Corp $4B PER - 
VCYT#23 Veracyte Inc $4B PER 37.0 
FAQ
What kind of company is BLLN?
BLLN belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of BLLN?
The market cap of BLLN is approximately $5.4B, ranking 1,321 within its sector.
What is the P/E ratio of BLLN?
BLLN has a P/E ratio of approximately 186.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BLLN?
BLLN has recorded a 52-week high of $150.44 and a low of $61.96.
